#Genprex #GPX-002 #diabetes gene therapy

Promising Developments in Diabetes Treatment by Genprex

Genprex, Inc., a clinical-stage gene therapy company, has announced initial positive results from its preclinical studies of GPX-002, a novel gene therapy aimed at treating Type 1 (T1D) and Type 2 diabetes (T2D). The company, which trades on the NASDAQ under the ticker GNPX, recently published fascinating preliminary data that could potentially revolutionize diabetes management for millions.

The Study: Methodologies and Results

Genprex's research team has been investigating the efficacy of GPX-002 in non-human primate (NHP) models, which are genetic analogs to humans and provide an outstanding platform for preclinical testing. The therapeutic approach involves using an adeno-associated virus (AAV) vector to deliver important genes—Pdx1 and MafA—directly into the pancreas, targeting the cellular mechanisms responsible for insulin production. This infusion protocol improves the delivery efficiency and reduces potential side effects associated with traditional administrations.

In the studies involving Type 2 diabetic NHPs, one received GPX-002 via an innovative infusion into the pancreatic duct, while the other had the therapy injected directly into the pancreas. The results were promising. The first NHP showed remarkable improvements in glucose tolerance over several months, ultimately achieving normal glucose levels. This indicates that GPX-002 is effective in rejuvenating exhausted beta cells, which are critical for insulin secretion and glucose metabolism.

Conversely, the second NHP, which received a direct pancreatic injection, demonstrated significant—but not complete—improvements in glucose tolerance. Although this route proved effective, the infusion method proved superior for maximal efficacy alignment.

The Scientific Backbone